JPMorgan Chase & Co. Has $1.06 Billion Stock Position in Natera, Inc. (NASDAQ:NTRA)

JPMorgan Chase & Co. lifted its holdings in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 43.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 6,701,425 shares of the medical research company's stock after purchasing an additional 2,036,396 shares during the quarter. JPMorgan Chase & Co. owned 5.08% of Natera worth $1,060,836,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in NTRA. Blue Trust Inc. raised its position in shares of Natera by 104.3% in the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company's stock valued at $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc increased its stake in Natera by 345.8% in the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company's stock valued at $34,000 after acquiring an additional 166 shares during the last quarter. EverSource Wealth Advisors LLC raised its position in Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company's stock valued at $52,000 after purchasing an additional 261 shares in the last quarter. Principal Securities Inc. lifted its stake in Natera by 20.7% during the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company's stock worth $54,000 after purchasing an additional 59 shares during the last quarter. Finally, True Wealth Design LLC acquired a new stake in shares of Natera in the 3rd quarter valued at $57,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Natera Trading Down 1.2 %

Shares of Natera stock traded down $1.70 during midday trading on Monday, reaching $142.24. The company had a trading volume of 1,193,891 shares, compared to its average volume of 1,703,579. The stock has a fifty day moving average price of $159.60 and a 200 day moving average price of $151.13. Natera, Inc. has a fifty-two week low of $83.13 and a fifty-two week high of $183.00. The firm has a market cap of $19.23 billion, a PE ratio of -80.82 and a beta of 1.80. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23.

Natera (NASDAQ:NTRA - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The medical research company reported ($0.41) EPS for the quarter, beating analysts' consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company had revenue of $476.10 million for the quarter, compared to analyst estimates of $447.91 million. On average, equities analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 78,553 shares of the firm's stock in a transaction on Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total value of $12,958,888.41. Following the completion of the sale, the chief executive officer now directly owns 267,629 shares in the company, valued at approximately $44,150,756.13. This trade represents a 22.69 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Michael Burkes Brophy sold 25,931 shares of the company's stock in a transaction dated Wednesday, January 22nd. The shares were sold at an average price of $164.97, for a total transaction of $4,277,837.07. Following the transaction, the chief financial officer now owns 109,665 shares in the company, valued at $18,091,435.05. This represents a 19.12 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 306,797 shares of company stock worth $48,940,883 in the last 90 days. Corporate insiders own 7.60% of the company's stock.

Analyst Ratings Changes

NTRA has been the subject of a number of research analyst reports. BTIG Research reissued a "buy" rating on shares of Natera in a report on Friday, February 28th. StockNews.com raised Natera from a "sell" rating to a "hold" rating in a research note on Wednesday, March 19th. Royal Bank of Canada began coverage on shares of Natera in a research note on Thursday, March 13th. They issued an "outperform" rating and a $251.00 price target on the stock. Guggenheim lifted their price target on shares of Natera from $170.00 to $200.00 and gave the company a "buy" rating in a report on Friday, January 17th. Finally, The Goldman Sachs Group increased their price objective on shares of Natera from $160.00 to $190.00 and gave the company a "buy" rating in a research note on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company. According to MarketBeat, Natera currently has a consensus rating of "Moderate Buy" and an average price target of $178.12.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.